DEK oncogene is overexpressed during melanoma progression

Summary DEK is an oncoprotein involved in a variety of cellular functions, such as DNA repair, replication, and transcriptional control. DEK is preferentially expressed in actively proliferating and malignant cells, including melanoma cell lines in which DEK was previously demonstrated to play a cri...

Full description

Saved in:
Bibliographic Details
Published in:Pigment cell and melanoma research 2017-03, Vol.30 (2), p.194-202
Main Authors: Riveiro‐Falkenbach, Erica, Ruano, Yolanda, García‐Martín, Rosa M., Lora, David, Cifdaloz, Metehan, Acquadro, Francesco, Ballestín, Claudio, Ortiz‐Romero, Pablo L., Soengas, María S., Rodríguez‐Peralto, José L.
Format: Article
Language:English
Subjects:
Biomarkers, Tumor - genetics
Biomarkers, Tumor - metabolism
Cell Proliferation
Chromosomal Proteins, Non-Histone - genetics
Chromosomal Proteins, Non-Histone - metabolism
DEK
Disease Progression
Female
Follow-Up Studies
Gene Expression Regulation, Neoplastic
Humans
Immunoenzyme Techniques
Lesions
Lymphatic Metastasis
Male
Melanoma
Melanoma - genetics
Melanoma - metabolism
Melanoma - pathology
Middle Aged
Neoplasm Staging
oncogene
Oncogene Proteins - genetics
Oncogene Proteins - metabolism
overexpression
Poly-ADP-Ribose Binding Proteins - genetics
Poly-ADP-Ribose Binding Proteins - metabolism
Prognosis
progression
Survival Rate
Tumor Cells, Cultured
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary DEK is an oncoprotein involved in a variety of cellular functions, such as DNA repair, replication, and transcriptional control. DEK is preferentially expressed in actively proliferating and malignant cells, including melanoma cell lines in which DEK was previously demonstrated to play a critical role in proliferation and chemoresistance. Still, the impact of this protein in melanoma progression remains unclear. Thus, we performed a comprehensive analysis of DEK expression in different melanocytic tumors. The immunostaining results of 303 tumors demonstrated negligible DEK expression in benign lesions. Conversely, malignant lesions, particularly in metastatic cases, were largely positive for DEK expression, which was partially associated with genomic amplification. Importantly, DEK overexpression was correlated with histological features of aggressiveness in primary tumors and poor prognosis in melanoma patients. In conclusion, our study provides new insight into the involvement of DEK in melanoma progression, as well as proof of concept for its potential application as a marker and therapeutic target of melanoma.
ISSN:1755-1471
1755-148X
DOI:10.1111/pcmr.12563